The positive sales surprise for Integra Lifesciences in Q1 2024, surpassing estimates by a notable margin, indicates strong revenue performance which is likely to be viewed positively by investors. The EPS meeting expectations confirms the company's ability to align with analyst forecasts, further stabilizing investor confidence. Together, these factors suggest a positive short-term impact on IART's stock price.